Breaking News
Home / About and Living / FDA Erring On The side Of Precaution.
FDA

FDA Erring On The side Of Precaution.

Diabetes is the fastest growing Pandemic
No More ‘Sadi-betes!’
While DDP-4 drugs used to lower blood sugar in adults with type 2 diabetes mellitus could cause the added discomfort of joint pains.
Toni Clarke in Washington reported last month that the FDA of USA identified (between Oct. 16, 2006 and Dec. 31, 2013) thirty-three cases of severe joint pain in patients DPP-4 inhibitors.
The FDA advises that patients should not stop taking their drugs but should contact their doctor if they experience severe and persistent joint pain.
Twenty-eight cases occurred with Merck’s Januvia, (sitagliptin). Merck is confident in the safety profile of sitagliptin and attributes the high number of cases, to it being the first in the market and also to it being the most widely prescribed drug, (eighty percent of DPP-4 prescriptions in the United States). Steven Cragle, spokesman said, “Merck takes all safety information seriously and we worked closely with the FDA on this request,”
You want it Eagle-eyed
We can ‘dia-beat-this!’
Five cases were reported with AstraZeneca Plc’s Onglyza (saxagliptin), two with Boehringer Ingelheim’s Tradjenta (linagliptin) and one with Takeda Pharmaceutical’s Nesina (alogliptin).
The FDA said that in 20 of the cases, the DPP-4 inhibitor was suspected as a cause of the pain and was discontinued within a month after the onset of symptoms. In eight of the remaining 13 cases, a period of 44 days to a year elapsed between the onset of symptoms and discontinuation of the drug.
Boehringer Ingelheim ‘s spokeswoman Emily Geary pointed out that clinical trials of Tradjenta “do not show an imbalance between linagliptin and placebo in musculoskeletal and connective tissue disorders or, more specifically, in joint disorders.”
A spokesman for AstraZeneca, Andrew Davis, said the company “works with health authorities and scientific experts to help ensure patients and physicians have a clear understanding of the risk-benefit profile of our medications.”
A spokesman for Takeda did not immediately respond to a request for comment.
E67 – Pharmaceuticals Do Not Agree With FDA, USA On Side Effects Of Dpp-4 Inhibitors – www.diabetic.today
Print Friendly, PDF & Email
Please follow and like us:
20

Check Also

Prediabetes Care Or Scare? Blood Sugar and Normality.

ShareStay near your optimum weight. Obesity is believed to account for 80-85 percent of the …

Featured Video Play Icon

Explaining Symptoms of Type 1 and Type 2

ShareThis film explains how the body processes the food we eat in order to provide …

Featured Video Play Icon

What is Epidemiology and Pathophysiology of Type 1 Diabetes

ShareEPIDEMIOLOGY There is a large geographical variation in the incidence of Type 1 diabetes. In …

Leave a Reply

Facebook Auto Publish Powered By : XYZScripts.com
Translate »
Social media & sharing icons powered by UltimatelySocial